Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial

Li, Bing; Fan, Ke; Zhang, Tonghe; Wu, Zhifeng; Zeng, Siming; Zhao, Mingwei; Ren, Qian; Zheng, Dongping; Wang, Lifei; Liu, Xiaoling; Han, Mei; Song, Yanping; Ye, Jian; Pei, Cheng; Yi, Jinglin; Wang, Xian; Peng, Hui; Zhang, Hong; Zhou, Zhanyu; Liang, Xiaoling; Yu, Fangliang; Wu, Miaoqin; Li, Chaopeng; Lei, Chunling; Hao, Jilong; Tang, Luosheng; Yuan, Huiping; Cai, Shanjun; Li, Qiuming; Zhong, Jingxiang; Li, Suyan; Liu, Lin; Ke, Min; Wang, Jing; Wang, Hui; Zhu, Mengli; Wang, Zenghua; Yan, Yang; Wang, Feng; Chen, Youxin

Published in

Springer, Ophthalmology and Therapy, 1(13), p. 353-366, 2023

DOI: 10.1007/s40123-023-00836-4

Tools

Export citation

Search in Google Scholar

Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial

Journal article published in 2023 by Bing Li, Ke Fan, Tonghe Zhang, Zhifeng Wu, Siming Zeng, Mingwei Zhao, Qian Ren, Dongping Zheng, Lifei Wang, Xiaoling Liu, Mei Han, Yanping Song, Jian Ye, Cheng Pei, Jinglin Yi and other authors.

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving allowed

Upload

Postprint: archiving allowed

Upload

Published version: archiving allowed

Upload

Policy details

Data provided by

Published in

Links

Tools

Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial